CABALETTA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.01 USD | -9.61% |
|
-17.47% | -51.50% |
| 03-22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
| 03-21 | Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 335.8 | 300.2 | 107.4 | 269.6 | 972.7 | 531.2 | - | - |
| Enterprise Value (EV) 1 | 199.6 | 191.6 | -14.85 | 163 | 972.7 | 273.4 | 350.5 | 305.6 |
| P/E ratio | -3.43 x | -8.67 x | -2.11 x | -5.11 x | -13.8 x | -5.82 x | -5.22 x | -5.06 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 95.6 x | 283 x |
| EV / Revenue | - | - | - | - | - | - | 63.1 x | 163 x |
| EV / EBITDA | -10.7 x | -5.72 x | 0.33 x | -3.06 x | -13.3 x | -2.85 x | -3.18 x | -2.4 x |
| EV / FCF | -11.9 x | -6.99 x | 0.42 x | -3.34 x | - | -3.07 x | -4.2 x | -2.77 x |
| FCF Yield | -8.39% | -14.3% | 238% | -30% | - | -32.5% | -23.8% | -36.1% |
| Price to Book | 2.43 x | 2.74 x | 0.93 x | 2.6 x | - | 2.73 x | 4.63 x | 3.02 x |
| Nbr of stocks (in thousands) | 24,034 | 24,055 | 28,332 | 29,141 | 42,849 | 48,249 | - | - |
| Reference price 2 | 13.97 | 12.48 | 3.790 | 9.250 | 22.70 | 11.01 | 11.01 | 11.01 |
| Announcement Date | 20-03-30 | 21-03-16 | 22-03-17 | 23-03-16 | 24-03-21 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 5.556 | 1.875 |
| EBITDA 1 | -18.58 | -33.48 | -45.52 | -53.18 | -73.23 | -95.76 | -110.1 | -127.4 |
| EBIT 1 | -18.68 | -33.83 | -46.31 | -54.14 | -74.66 | -98.52 | -112.6 | -138.5 |
| Operating Margin | - | - | - | - | - | - | -2,027.57% | -7,388.03% |
| Earnings before Tax (EBT) 1 | -16.94 | -33.34 | -46.29 | -52.98 | -67.68 | -92.4 | -108.7 | -136.6 |
| Net income 1 | -22.27 | -33.34 | -46.29 | -52.98 | -67.68 | -92.39 | -108.7 | -136.6 |
| Net margin | - | - | - | - | - | - | -1,957.38% | -7,284.45% |
| EPS 2 | -4.070 | -1.440 | -1.800 | -1.810 | -1.650 | -1.892 | -2.110 | -2.177 |
| Free Cash Flow 1 | -16.74 | -27.4 | -35.28 | -48.83 | - | -88.97 | -83.48 | -110.4 |
| FCF margin | - | - | - | - | - | - | -1,502.55% | -5,885.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20-03-30 | 21-03-16 | 22-03-17 | 23-03-16 | 24-03-21 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | -22.81 | -23.28 | -24.07 | -25.06 | -26.06 | - |
| EBIT 1 | -11.56 | -13.89 | -13 | -13.06 | -11.78 | -16.3 | -16.96 | -15.89 | -18.67 | -23.15 | -22.96 | -24.11 | -25.28 | -26.4 | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -11.56 | -13.89 | -12.95 | -12.91 | -11.43 | -15.69 | -15.85 | -14.49 | -16.45 | -20.89 | -21.35 | -22.57 | -23.78 | -24.92 | - |
| Net income 1 | -11.56 | -13.89 | -12.95 | -12.91 | -11.43 | -15.69 | -15.85 | -14.49 | -16.45 | -20.89 | -21.35 | -22.57 | -23.78 | -24.93 | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.4500 | -0.4900 | -0.4500 | -0.4500 | -0.3900 | -0.5200 | -0.4500 | -0.3700 | -0.3700 | -0.4600 | -0.4756 | -0.4722 | -0.4700 | -0.4822 | -0.6700 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-01 | 22-03-17 | 22-05-12 | 22-08-11 | 22-11-10 | 23-03-16 | 23-05-11 | 23-08-10 | 23-11-09 | 24-03-21 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 136 | 109 | 122 | 107 | - | 258 | 181 | 226 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -16.7 | -27.4 | -35.3 | -48.8 | - | -89 | -83.5 | -110 |
| ROE (net income / shareholders' equity) | -26.6% | -26.9% | -40.7% | -47.6% | - | -44.2% | -56.5% | -57.8% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 5.760 | 4.550 | 4.080 | 3.560 | - | 4.040 | 2.380 | 3.640 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.69 | 0.64 | 1.17 | 2.45 | - | 0.8 | 4.5 | 7 |
| Capex / Sales | - | - | - | - | - | - | 81% | 373.33% |
| Announcement Date | 20-03-30 | 21-03-16 | 22-03-17 | 23-03-16 | 24-03-21 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
11.01
USD
Average target price
34.5
USD
Spread / Average Target
+213.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -51.50% | 531M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CABA Stock
- Financials Cabaletta Bio, Inc.
